OSTX Stock Forecast & Price Target

OS Therapies is a promising company with potential in their pipeline of product candidates addressing solid cancers, particularly osteosarcoma. While they have a heavy cost structure and financial concerns, their positive update and potential EMA CMA decision in 2026 could lead to European peak sales potential above $300M and a potential PRV eligibility. However, the success of their accelerated approval path depends on their ability to execute against regulatory milestones and convert Phase 2b and biomarker data. There are also potential risks, such as clinical/regulatory risk, partnership and financial risk, commercial risk, legal and intellectual property risk, and market share risk, to consider.

OS Therapies is heavily reliant on OST-HER2, a yet-to-be approved immunotherapy drug with uncertain efficacy and safety data, as its main source of potential revenue in the near future. Additionally, the company's financials show a lack of cash flow and significant debt, which may make it difficult for them to continue developing and commercializing their drug candidates without additional funding. With these risks and uncertainties in mind, a negative outlook on OS Therapies's stock seems reasonable in the current stage of the company's development.